Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO and Bortezomib in Relapsed or Refractory Neuroblastoma
NCT02139397Phase 2Completed
- Start
- Jun 2014
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eflornithine in neuroblastoma. Started Jun 2014; status: completed.
02
Drugs
eflornithine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02139397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02139397.